[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @StephenVLiu Stephen V Liu, MD Stephen V Liu, MD posts on X about cns, approved, rates, rr the most. They currently have XXXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::377425889/interactions)  - X Week XXXXXX -XX% - X Month XXXXXXX +56% - X Months XXXXXXX +8.30% - X Year XXXXXXX +0.03% ### Mentions: XX [#](/creator/twitter::377425889/posts_active)  - X Month X -XX% - X Months XX -XXXX% - X Year XXX +84% ### Followers: XXXXXX [#](/creator/twitter::377425889/followers)  - X Week XXXXXX +0.31% - X Month XXXXXX +1.10% - X Months XXXXXX +7.40% - X Year XXXXXX +12% ### CreatorRank: XXXXXXX [#](/creator/twitter::377425889/influencer_rank)  ### Social Influence [#](/creator/twitter::377425889/influence) --- **Social category influence** [countries](/list/countries) XXXX% **Social topic influence** [cns](/topic/cns) 2.67%, [approved](/topic/approved) #338, [rates](/topic/rates) #784, [rr](/topic/rr) 1.33%, [dor](/topic/dor) #83, [notable](/topic/notable) #74, [mdt](/topic/mdt) 1.33%, [china](/topic/china) 1.33%, [aes](/topic/aes) 1.33%, [iii](/topic/iii) #254 **Top accounts mentioned or mentioned by** [@larvol](/creator/undefined) [@lungcajournal](/creator/undefined) [@oncoalert](/creator/undefined) [@martinreck2](/creator/undefined) [@enriquetafelip](/creator/undefined) [@iaslc](/creator/undefined) [@jtoonline](/creator/undefined) [@drjnaidoo](/creator/undefined) [@drshieldsmd](/creator/undefined) [@clinicallung](/creator/undefined) [@shirishgadgeel](/creator/undefined) [@drsanjaypopat](/creator/undefined) [@alexdrilon](/creator/undefined) [@tonymok9](/creator/undefined) [@bensolomon1](/creator/undefined) [@jcoasco](/creator/undefined) [@fordepatrick](/creator/undefined) [@alfdoc2](/creator/undefined) [@chulkimmd](/creator/undefined) [@iliashouda](/creator/undefined) ### Top Social Posts [#](/creator/twitter::377425889/posts) --- Top posts by engagements in the last XX hours "#ESMO25 Dr. Ying Liu will present abstract 1848MO results from the phaes II FURMO-003 study of firmonertinib (aka furmonertinib) in pts with previously treated EGFR exon XX NSCLC. ITT RR XXXX% DCR XX% DOR 8.3m PFS 8.3m OS 21.2m diarrhea in 64.8%. #ESMOAmbassadors" [X Link](https://x.com/StephenVLiu/status/1977732432959799772) [@StephenVLiu](/creator/x/StephenVLiu) 2025-10-13T13:45Z 28.7K followers, 2713 engagements "#ESMO25 Dr. @Ilias_Houda presents 1851MO the PAULIEN trial: 1L pembro +/- chemo in PD-L1 high NSCLC. Stopped early for futility. RR at 6wks favored pembro/chemo (33% vs 23%) but no difference at 12wks (48% vs 47%). PFS HR XXXX OS HR XXXX. G3+ TRAE XX% vs 35%. #ESMOAmbassadors" [X Link](https://x.com/StephenVLiu/status/1977734464936554509) [@StephenVLiu](/creator/x/StephenVLiu) 2025-10-13T13:53Z 28.6K followers, 2464 engagements "PACIFIC-2 results @JCO_ASCO - while consolidation durvalumab after concurrent chemoradiation for NSCLC significantly improves PFS and OS simultaneous durvalumab + chemoradiation did not improve outcomes over CRT alone: PFS HR XXXX (ns) OS HR 1.03" [X Link](https://x.com/StephenVLiu/status/1978027920149934474) [@StephenVLiu](/creator/x/StephenVLiu) 2025-10-14T09:19Z 28.6K followers, 5100 engagements "How do we approach neoadjuvant and perioperative immunotherapy in PD-L1 negative resectable NSCLC Dr. @FordePatrick reviews the data at #BTGGlobalLung2025 and raises key controversies. Some conflicting datasets suggest hidden biomarkers. Important to define exact benefit" [X Link](https://x.com/StephenVLiu/status/1978722373558837517) [@StephenVLiu](/creator/x/StephenVLiu) 2025-10-16T07:19Z 28.7K followers, 3017 engagements "Dr. @FedericoCappuz1 brilliantly presents updates and controversies for uncommon and exon XX EGFR mutations at #BTGGlobalLung2025. Amivantamab + chemotherapy is the 1L standard but new agents arriving may disrupt the paradigm. Need to watch toxicity resistance CNS efficacy" [X Link](https://x.com/StephenVLiu/status/1978459213757104143) [@StephenVLiu](/creator/x/StephenVLiu) 2025-10-15T13:53Z 28.7K followers, 2717 engagements "Dr. @ZPiotrowskaMD discusses NORTHSTAR #ESMO25 - impressive PFS benefit in #EGFR NSCLC when local consolidation therapy added but notable heterogeneity. Pt selection important need uniform definitions biomarkers (radiomics). Encouraging results here. #ESMOAmbassadors" [X Link](https://x.com/StephenVLiu/status/1979196961887502755) [@StephenVLiu](/creator/x/StephenVLiu) 2025-10-17T14:45Z 28.7K followers, 11.6K engagements "Impressive results from MDT-BRIDGE at #ESMO25 from Dr. @MartinReck2. Pts with resectable or borderline had X cycles of durvalumab + chemo then reassessed at MDT. If resectable at start XX% remained resectable. If borderline XX% were then felt to be resectable. #ESMOAmbassadors" [X Link](https://x.com/StephenVLiu/status/1979450481400516850) [@StephenVLiu](/creator/x/StephenVLiu) 2025-10-18T07:32Z 28.7K followers, 20.8K engagements "#ESMO25 Brain mets present in XX% of pts overall. For those with no brain metastases X% developed brain metastases as site of first progression. Studies ongoing (cohort G) in pts with measurable CNS disease to report CNS RR and intracranial PFS hopefully. #ESMOAmbassadors" [X Link](https://x.com/StephenVLiu/status/1979814290392814079) [@StephenVLiu](/creator/x/StephenVLiu) 2025-10-19T07:38Z 28.7K followers, XX engagements "#ESMO25 Included XX pts with HER2 TKD mt (66% YVMA) treated with 1L zongertinib 120mg - RR XX% DCR XX% () time to response 1.4m XX% still on treatment median DOR/PFS not reached 6m DOR XX% 6m PFS 79%. Impressive numbers here. #ESMOAmbassadors" [X Link](https://x.com/StephenVLiu/status/1979819148491596017) [@StephenVLiu](/creator/x/StephenVLiu) 2025-10-19T07:57Z 28.7K followers, XXX engagements "#ESMO25 Dr. @MLJohnsonMD2 updates PHAROS: encorafenib + binimetinib in #BRAF V600E NSCLC. 1L RR XX% DOR 40m () PFS 30.4m OS 47.6m. Later line RR XX% DOR 16.7m PFS 9.3m OS 22.7m. Pyrexia in only X% main toxicities nausea diarrhea. Impressive update #ESMOAmbassadors" [X Link](https://x.com/StephenVLiu/status/1979886824547041281) [@StephenVLiu](/creator/x/StephenVLiu) 2025-10-19T12:26Z 28.7K followers, 7306 engagements "Dr. Shun Lu delivers HARMONi-6 results at #ESMO25: first line ivonescimab + chemotherapy vs tislelizumab (PD-1 approved by China EMA) + chemo for advanced squamous NSCLC. Chemotherapy + immunotherapy is our standard of care but squamous outcomes remain poor. #ESMOAmbassadors" [X Link](https://x.com/StephenVLiu/status/1980155716842217814) [@StephenVLiu](/creator/x/StephenVLiu) 2025-10-20T06:14Z 28.7K followers, 2012 engagements "Nice perspective in discussion by Dr. @finn_corinne at #ESMO25 on SKYSCRAPER-03 where adding tiragolumab did not improve outcomes over standard PACIFIC and MDT-BRIDGE reassured by only X% of people not having either surgery or definitive chemoradiation. #ESMOAmbassadors" [X Link](https://x.com/StephenVLiu/status/1979454294655906084) [@StephenVLiu](/creator/x/StephenVLiu) 2025-10-18T07:47Z 28.7K followers, 2209 engagements "#ESMO25 HARMONi-6 meets its primary endpoint improving PFS from 6.9m to 11.1m HR XXXX with benefit across PD-L1 strata: negative PFS XXXX low PFS XXXX high PFS XXXX with higher RR (75.9% vs 66.5%) and DOR (11.2m vs 8.4m). #ESMOAmbassadors" [X Link](https://x.com/StephenVLiu/status/1980155720105668875) [@StephenVLiu](/creator/x/StephenVLiu) 2025-10-20T06:14Z 28.7K followers, XXX engagements "#ESMO25 Similar rates of G3+ treatment related AEs but no discontinuation due to related toxicity. Most common toxicity was hematologic in both arms. Sac-TMT with more stomatitis (62% mostly low grade) ocular toxicity in XX% (grade 1-2) no cases of ILD. #ESMOAmbassadors" [X Link](https://x.com/StephenVLiu/status/1980160454204023063) [@StephenVLiu](/creator/x/StephenVLiu) 2025-10-20T06:33Z 28.7K followers, XXX engagements "#ESMO25 These are tremendous results over a strong control arm. Await more details on resistance patterns of progression CNS efficacy and outcomes longer survival follow up - but I feel these are practice changing where sac-TMT is available. #ESMOAmbassadors" [X Link](https://x.com/StephenVLiu/status/1980160457664307517) [@StephenVLiu](/creator/x/StephenVLiu) 2025-10-20T06:33Z 28.7K followers, XXX engagements "Akeso reports Phase III HARMONi-A trial positive for survival. Ivonescimab (PD1/VEGF bispecific) + chemotherapy vs chemo in #EGFR NSCLC post TKI already showed PFS benefit (7.1m vs 4.8m) but OS was in question. Full results to be presented at #WCLC25" [X Link](https://x.com/StephenVLiu/status/1960957912748044313) [@StephenVLiu](/creator/x/StephenVLiu) 2025-08-28T06:49Z 28.7K followers, 4551 engagements "We will face a shortage of oncologists as projected cancer cases rise and number of oncologists decreasing relative to demand. XX% of oncologists are 64y and older. Number of oncologists currently on pace to meet only XX% of demand in next XX years. Gaps will widen" [X Link](https://x.com/StephenVLiu/status/1975906472690331753) [@StephenVLiu](/creator/x/StephenVLiu) 2025-10-08T12:49Z 28.7K followers, 61.9K engagements "Be sure to join Drs. @EnriquetaFelip @LuisPaz_Ares and me at #ESMO25 on Saturday October XX 6:30pm in Hall XX as we discuss recent advances in #SCLC. Lots of emerging data to put together - join us for a lively discussion" [X Link](https://x.com/StephenVLiu/status/1977689136447603117) [@StephenVLiu](/creator/x/StephenVLiu) 2025-10-13T10:53Z 28.7K followers, 3177 engagements "Dr. @HendriksLizza leads a discussion on neoadjuvant perioperative & adjuvant immunotherapy for early stage NSCLC at #BTGGlobalLung2025. Open questions on how PD-L1 and co-mutations should impact strategies and the role for consolidation IO after neoadjuvant. #MJHLifeSciences" [X Link](https://x.com/StephenVLiu/status/1978717520191201646) [@StephenVLiu](/creator/x/StephenVLiu) 2025-10-16T06:59Z 28.7K followers, 1715 engagements "Dr. @LeXiuning reflects on #KRAS G12C NSCLC at #BTGGlobalLung2025. Sotorasib and adagrasib standard 2L - newer agents coming quickly and will be a race to see who (safely) enters 1L space with immunotherapy first. Other off inhibitors pan RAS inhibitors on the way" [X Link](https://x.com/StephenVLiu/status/1978754422801883483) [@StephenVLiu](/creator/x/StephenVLiu) 2025-10-16T09:26Z 28.7K followers, 2511 engagements "Dr. @EnriquetaFelip discusses #ALK in NSCLC at #BTGGlobalLung2025. Many active TKIs with lorlatinib showing best efficacy to date - neladalkib (NVL-655) showing promise as next gen agent. Early stage use standard after ALINA - await update at #ESMO25" [X Link](https://x.com/StephenVLiu/status/1978758794160005206) [@StephenVLiu](/creator/x/StephenVLiu) 2025-10-16T09:43Z 28.7K followers, 2837 engagements "Dr. @JordiRemon at #BTGGlobalLung2025 leads a discussion on rare alterations. MTAP deletions now relevant with promising agents. #NRG1 fusions predict poor outcomes in NSCLC with standard therapies but zenocutuzumab now approved. STK11 mt - should we pursue dual checkpoint" [X Link](https://x.com/StephenVLiu/status/1978769464859521363) [@StephenVLiu](/creator/x/StephenVLiu) 2025-10-16T10:26Z 28.7K followers, 2192 engagements "#ESMO25 Safety notable for diarrhea in XX% of pts with XX% grade X. However in cohort D G3 diarrhea was XX% but in cohort F (treatment naive) G3 diarrhea was 5%. Could this reflect proximity to prior immunotherapy And no cases of pneumonitis. #ESMOAmbassadors" [X Link](https://x.com/StephenVLiu/status/1979814293370790067) [@StephenVLiu](/creator/x/StephenVLiu) 2025-10-19T07:38Z 28.7K followers, XXX engagements "#ESMO25 Primary related toxicities are diarrhea seen in XX% (3% grade 3+) rash in XX% (no G3) and LFT elevation (AST XX% with X% G3 ALT XX% with X% G3). Dose reduction in XX% discontinuation due to AE in X% two cases of ILD noted (3% both grade 2). #ESMOAmbassadors" [X Link](https://x.com/StephenVLiu/status/1979819151607955829) [@StephenVLiu](/creator/x/StephenVLiu) 2025-10-19T07:57Z 28.7K followers, XXX engagements "#ESMO25 Sac-TMT with marked improvement in PFS over plat + pemetrexed with PFS HR XXXX (8.3m vs 4.3m 1y PFS XX% vs 8%) higher RR (61% vs 43%) and an OS benefit (HR XXXX 18m OS rate XX% vs XX% median NR) even with high rates of 3L treatment in control arm. #ESMOAmbassadors" [X Link](https://x.com/StephenVLiu/status/1980160450777301173) [@StephenVLiu](/creator/x/StephenVLiu) 2025-10-20T06:33Z 28.7K followers, XXX engagements "#ESMO25 Dr. @Ilias_Houda presents randomized phase III PAULIEN trial of 1L pembro vs chemo + pembro in PD-L1 high NSCLC. Only XX patients as study stopped early for futility. #ESMOAmbassadors" [X Link](https://x.com/StephenVLiu/status/1980227001542992172) [@StephenVLiu](/creator/x/StephenVLiu) 2025-10-20T10:58Z 28.7K followers, 1850 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@StephenVLiu Stephen V Liu, MD
Stephen V Liu, MD posts on X about cns, approved, rates, rr the most. They currently have XXXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXXX -XX%
- X Month XXXXXXX +56%
- X Months XXXXXXX +8.30%
- X Year XXXXXXX +0.03%
Mentions: XX #
- X Month X -XX%
- X Months XX -XXXX%
- X Year XXX +84%
Followers: XXXXXX #
- X Week XXXXXX +0.31%
- X Month XXXXXX +1.10%
- X Months XXXXXX +7.40%
- X Year XXXXXX +12%
CreatorRank: XXXXXXX #
Social Influence #
Social category influence countries XXXX%
Social topic influence cns 2.67%, approved #338, rates #784, rr 1.33%, dor #83, notable #74, mdt 1.33%, china 1.33%, aes 1.33%, iii #254
Top accounts mentioned or mentioned by @larvol @lungcajournal @oncoalert @martinreck2 @enriquetafelip @iaslc @jtoonline @drjnaidoo @drshieldsmd @clinicallung @shirishgadgeel @drsanjaypopat @alexdrilon @tonymok9 @bensolomon1 @jcoasco @fordepatrick @alfdoc2 @chulkimmd @iliashouda
Top Social Posts #
Top posts by engagements in the last XX hours
"#ESMO25 Dr. Ying Liu will present abstract 1848MO results from the phaes II FURMO-003 study of firmonertinib (aka furmonertinib) in pts with previously treated EGFR exon XX NSCLC. ITT RR XXXX% DCR XX% DOR 8.3m PFS 8.3m OS 21.2m diarrhea in 64.8%. #ESMOAmbassadors"
X Link @StephenVLiu 2025-10-13T13:45Z 28.7K followers, 2713 engagements
"#ESMO25 Dr. @Ilias_Houda presents 1851MO the PAULIEN trial: 1L pembro +/- chemo in PD-L1 high NSCLC. Stopped early for futility. RR at 6wks favored pembro/chemo (33% vs 23%) but no difference at 12wks (48% vs 47%). PFS HR XXXX OS HR XXXX. G3+ TRAE XX% vs 35%. #ESMOAmbassadors"
X Link @StephenVLiu 2025-10-13T13:53Z 28.6K followers, 2464 engagements
"PACIFIC-2 results @JCO_ASCO - while consolidation durvalumab after concurrent chemoradiation for NSCLC significantly improves PFS and OS simultaneous durvalumab + chemoradiation did not improve outcomes over CRT alone: PFS HR XXXX (ns) OS HR 1.03"
X Link @StephenVLiu 2025-10-14T09:19Z 28.6K followers, 5100 engagements
"How do we approach neoadjuvant and perioperative immunotherapy in PD-L1 negative resectable NSCLC Dr. @FordePatrick reviews the data at #BTGGlobalLung2025 and raises key controversies. Some conflicting datasets suggest hidden biomarkers. Important to define exact benefit"
X Link @StephenVLiu 2025-10-16T07:19Z 28.7K followers, 3017 engagements
"Dr. @FedericoCappuz1 brilliantly presents updates and controversies for uncommon and exon XX EGFR mutations at #BTGGlobalLung2025. Amivantamab + chemotherapy is the 1L standard but new agents arriving may disrupt the paradigm. Need to watch toxicity resistance CNS efficacy"
X Link @StephenVLiu 2025-10-15T13:53Z 28.7K followers, 2717 engagements
"Dr. @ZPiotrowskaMD discusses NORTHSTAR #ESMO25 - impressive PFS benefit in #EGFR NSCLC when local consolidation therapy added but notable heterogeneity. Pt selection important need uniform definitions biomarkers (radiomics). Encouraging results here. #ESMOAmbassadors"
X Link @StephenVLiu 2025-10-17T14:45Z 28.7K followers, 11.6K engagements
"Impressive results from MDT-BRIDGE at #ESMO25 from Dr. @MartinReck2. Pts with resectable or borderline had X cycles of durvalumab + chemo then reassessed at MDT. If resectable at start XX% remained resectable. If borderline XX% were then felt to be resectable. #ESMOAmbassadors"
X Link @StephenVLiu 2025-10-18T07:32Z 28.7K followers, 20.8K engagements
"#ESMO25 Brain mets present in XX% of pts overall. For those with no brain metastases X% developed brain metastases as site of first progression. Studies ongoing (cohort G) in pts with measurable CNS disease to report CNS RR and intracranial PFS hopefully. #ESMOAmbassadors"
X Link @StephenVLiu 2025-10-19T07:38Z 28.7K followers, XX engagements
"#ESMO25 Included XX pts with HER2 TKD mt (66% YVMA) treated with 1L zongertinib 120mg - RR XX% DCR XX% () time to response 1.4m XX% still on treatment median DOR/PFS not reached 6m DOR XX% 6m PFS 79%. Impressive numbers here. #ESMOAmbassadors"
X Link @StephenVLiu 2025-10-19T07:57Z 28.7K followers, XXX engagements
"#ESMO25 Dr. @MLJohnsonMD2 updates PHAROS: encorafenib + binimetinib in #BRAF V600E NSCLC. 1L RR XX% DOR 40m () PFS 30.4m OS 47.6m. Later line RR XX% DOR 16.7m PFS 9.3m OS 22.7m. Pyrexia in only X% main toxicities nausea diarrhea. Impressive update #ESMOAmbassadors"
X Link @StephenVLiu 2025-10-19T12:26Z 28.7K followers, 7306 engagements
"Dr. Shun Lu delivers HARMONi-6 results at #ESMO25: first line ivonescimab + chemotherapy vs tislelizumab (PD-1 approved by China EMA) + chemo for advanced squamous NSCLC. Chemotherapy + immunotherapy is our standard of care but squamous outcomes remain poor. #ESMOAmbassadors"
X Link @StephenVLiu 2025-10-20T06:14Z 28.7K followers, 2012 engagements
"Nice perspective in discussion by Dr. @finn_corinne at #ESMO25 on SKYSCRAPER-03 where adding tiragolumab did not improve outcomes over standard PACIFIC and MDT-BRIDGE reassured by only X% of people not having either surgery or definitive chemoradiation. #ESMOAmbassadors"
X Link @StephenVLiu 2025-10-18T07:47Z 28.7K followers, 2209 engagements
"#ESMO25 HARMONi-6 meets its primary endpoint improving PFS from 6.9m to 11.1m HR XXXX with benefit across PD-L1 strata: negative PFS XXXX low PFS XXXX high PFS XXXX with higher RR (75.9% vs 66.5%) and DOR (11.2m vs 8.4m). #ESMOAmbassadors"
X Link @StephenVLiu 2025-10-20T06:14Z 28.7K followers, XXX engagements
"#ESMO25 Similar rates of G3+ treatment related AEs but no discontinuation due to related toxicity. Most common toxicity was hematologic in both arms. Sac-TMT with more stomatitis (62% mostly low grade) ocular toxicity in XX% (grade 1-2) no cases of ILD. #ESMOAmbassadors"
X Link @StephenVLiu 2025-10-20T06:33Z 28.7K followers, XXX engagements
"#ESMO25 These are tremendous results over a strong control arm. Await more details on resistance patterns of progression CNS efficacy and outcomes longer survival follow up - but I feel these are practice changing where sac-TMT is available. #ESMOAmbassadors"
X Link @StephenVLiu 2025-10-20T06:33Z 28.7K followers, XXX engagements
"Akeso reports Phase III HARMONi-A trial positive for survival. Ivonescimab (PD1/VEGF bispecific) + chemotherapy vs chemo in #EGFR NSCLC post TKI already showed PFS benefit (7.1m vs 4.8m) but OS was in question. Full results to be presented at #WCLC25"
X Link @StephenVLiu 2025-08-28T06:49Z 28.7K followers, 4551 engagements
"We will face a shortage of oncologists as projected cancer cases rise and number of oncologists decreasing relative to demand. XX% of oncologists are 64y and older. Number of oncologists currently on pace to meet only XX% of demand in next XX years. Gaps will widen"
X Link @StephenVLiu 2025-10-08T12:49Z 28.7K followers, 61.9K engagements
"Be sure to join Drs. @EnriquetaFelip @LuisPaz_Ares and me at #ESMO25 on Saturday October XX 6:30pm in Hall XX as we discuss recent advances in #SCLC. Lots of emerging data to put together - join us for a lively discussion"
X Link @StephenVLiu 2025-10-13T10:53Z 28.7K followers, 3177 engagements
"Dr. @HendriksLizza leads a discussion on neoadjuvant perioperative & adjuvant immunotherapy for early stage NSCLC at #BTGGlobalLung2025. Open questions on how PD-L1 and co-mutations should impact strategies and the role for consolidation IO after neoadjuvant. #MJHLifeSciences"
X Link @StephenVLiu 2025-10-16T06:59Z 28.7K followers, 1715 engagements
"Dr. @LeXiuning reflects on #KRAS G12C NSCLC at #BTGGlobalLung2025. Sotorasib and adagrasib standard 2L - newer agents coming quickly and will be a race to see who (safely) enters 1L space with immunotherapy first. Other off inhibitors pan RAS inhibitors on the way"
X Link @StephenVLiu 2025-10-16T09:26Z 28.7K followers, 2511 engagements
"Dr. @EnriquetaFelip discusses #ALK in NSCLC at #BTGGlobalLung2025. Many active TKIs with lorlatinib showing best efficacy to date - neladalkib (NVL-655) showing promise as next gen agent. Early stage use standard after ALINA - await update at #ESMO25"
X Link @StephenVLiu 2025-10-16T09:43Z 28.7K followers, 2837 engagements
"Dr. @JordiRemon at #BTGGlobalLung2025 leads a discussion on rare alterations. MTAP deletions now relevant with promising agents. #NRG1 fusions predict poor outcomes in NSCLC with standard therapies but zenocutuzumab now approved. STK11 mt - should we pursue dual checkpoint"
X Link @StephenVLiu 2025-10-16T10:26Z 28.7K followers, 2192 engagements
"#ESMO25 Safety notable for diarrhea in XX% of pts with XX% grade X. However in cohort D G3 diarrhea was XX% but in cohort F (treatment naive) G3 diarrhea was 5%. Could this reflect proximity to prior immunotherapy And no cases of pneumonitis. #ESMOAmbassadors"
X Link @StephenVLiu 2025-10-19T07:38Z 28.7K followers, XXX engagements
"#ESMO25 Primary related toxicities are diarrhea seen in XX% (3% grade 3+) rash in XX% (no G3) and LFT elevation (AST XX% with X% G3 ALT XX% with X% G3). Dose reduction in XX% discontinuation due to AE in X% two cases of ILD noted (3% both grade 2). #ESMOAmbassadors"
X Link @StephenVLiu 2025-10-19T07:57Z 28.7K followers, XXX engagements
"#ESMO25 Sac-TMT with marked improvement in PFS over plat + pemetrexed with PFS HR XXXX (8.3m vs 4.3m 1y PFS XX% vs 8%) higher RR (61% vs 43%) and an OS benefit (HR XXXX 18m OS rate XX% vs XX% median NR) even with high rates of 3L treatment in control arm. #ESMOAmbassadors"
X Link @StephenVLiu 2025-10-20T06:33Z 28.7K followers, XXX engagements
"#ESMO25 Dr. @Ilias_Houda presents randomized phase III PAULIEN trial of 1L pembro vs chemo + pembro in PD-L1 high NSCLC. Only XX patients as study stopped early for futility. #ESMOAmbassadors"
X Link @StephenVLiu 2025-10-20T10:58Z 28.7K followers, 1850 engagements